177 related articles for article (PubMed ID: 24995276)
1. The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Jung JY; Kim HY; Han B; Choi DR; Zang DY; Kim HJ
Biomed Res Int; 2014; 2014():237698. PubMed ID: 24995276
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Koh Y; Lee SY; Kim I; Kwon JH; Yoon SS; Park S; Chung MH; Suh SY; Kim KS; Kim HS
Cancer Chemother Pharmacol; 2014 Sep; 74(3):653-7. PubMed ID: 25096796
[TBL] [Abstract][Full Text] [Related]
4. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Hashimoto N; Yokoyama K; Sadahira K; Ueda T; Tsukada Y; Okamoto S
Int J Hematol; 2012 Dec; 96(6):758-63. PubMed ID: 23179905
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Cavaletti G; Jakubowiak AJ
Leuk Lymphoma; 2010 Jul; 51(7):1178-87. PubMed ID: 20497001
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Argyriou AA; Iconomou G; Kalofonos HP
Blood; 2008 Sep; 112(5):1593-9. PubMed ID: 18574024
[TBL] [Abstract][Full Text] [Related]
8. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
9. Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
Kamimura T; Miyamoto T; Yokota N; Takashima S; Chong Y; Ito Y; Akashi K
Eur J Haematol; 2013 Feb; 90(2):157-61. PubMed ID: 23240903
[TBL] [Abstract][Full Text] [Related]
10. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Cartoni C; Brunetti GA; Federico V; Efficace F; Grammatico S; Tendas A; Scaramucci L; Cupelli L; D'Elia GM; Truini A; Niscola P; Petrucci MT
Support Care Cancer; 2012 Oct; 20(10):2621-6. PubMed ID: 22699304
[TBL] [Abstract][Full Text] [Related]
11. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
12. Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Cho J; Kang D; Lee JY; Kim K; Kim SJ
Support Care Cancer; 2014 Oct; 22(10):2669-75. PubMed ID: 24771302
[TBL] [Abstract][Full Text] [Related]
13. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC
Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
15. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
17. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Berkowitz A; Walker S
Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
[TBL] [Abstract][Full Text] [Related]
20. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Harrison SJ; Quach H; Link E; Seymour JF; Ritchie DS; Ruell S; Dean J; Januszewicz H; Johnstone R; Neeson P; Dickinson M; Nichols J; Prince HM
Blood; 2011 Dec; 118(24):6274-83. PubMed ID: 21911830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
